Summary of Key Information:
Reporting Period: Quarter ended June 30, 2026
Nature of Filing / Announcement: Financial Results Disclosure
Audit Opinion:
Clean opinion - Limited review report from Deloitte Haskins & Sells LLP with no modifications or qualifications.
Key Financial Highlights [₹ in million]:
Standalone Results:
Revenue from Operations: ₹71,719.0 million (26% increase from Q1 FY26: ₹57,085.9 million)
- Sales/Income from Operations: ₹71,124.6 million
- Other Operating Income: ₹594.4 million
Total Income: ₹72,743.8 million
EBITDA: Not explicitly disclosed
Net Profit: ₹27,146.0 million (28% increase from Q1 FY26: ₹21,280.7 million)
EPS (Basic): ₹59.37 (Before and after exceptional items)
EPS (Diluted): ₹59.27 (Before and after exceptional items)
Other Equity: ₹300,423.3 million
Cash and Cash Equivalents: Not specified
Debt: Not specified
Consolidated Results:
Revenue from Operations: ₹82,768.9 million (32% increase from Q1 FY26: ₹62,683.4 million)
Total Income: ₹84,072.1 million
Net Profit: ₹14,169.8 million
- Attributable to Owners: ₹14,150.0 million
- Non-Controlling Interest: ₹19.8 million
EPS (Basic): ₹30.95
EPS (Diluted): ₹30.89
Other Equity: ₹223,568.3 million
Segment-wise Performance [₹ in million]:
Pharmaceuticals Segment:
Revenue: ₹82,343.5 million (Q1 FY27)
Segment Profit: ₹20,605.6 million (Q1 FY27)
Others Segment:
Revenue: ₹430.3 million (Q1 FY27)
Segment Loss: ₹(432.0) million (Q1 FY27)
Total Assets (Pharmaceuticals): ₹406,033.0 million
Total Liabilities (Pharmaceuticals): ₹167,384.1 million
Corporate Actions:
Dividend: Not declared
Share Issuance: 53,425 equity shares of ₹2 each allotted upon exercise of vested stock options under ESOPs, increasing paid-up capital by ₹0.1 million and securities premium by ₹76.9 million.
Other Significant Information:
Acquisitions:
- Acquired VISUfarma B.V., Netherlands through Nanomi B.V. on April 01, 2026 for ₹20,902.7 million (€192.8 million)
- Fair value of intangibles: ₹15,971.1 million
- Deferred tax liability: ₹3,992.8 million
- Goodwill: ₹6,030.2 million
Litigation Matters:
- Settled one antitrust litigation matter in April 2026 for ₹2,654.1 million (USD 30.0 million) without admission of liability
- Cumulative provision for antitrust litigation matters: ₹5,816.9 million (USD 65.8 million) at March 31, 2026
- Settlement with Astellas regarding Mirabegron ER Tablets: Total payment of ₹8,475.5 million (USD 90.0 million), with ₹1,364.7 million expensed and ₹7,110.8 million capitalized as Prepaid Option
Labor Code Impact:
Recognized incremental cost of ₹496.4 million (standalone) and ₹512.2 million (consolidated) during FY26 due to implementation of New Labour Codes effective November 21, 2025
Business Transfers:
Transferred OTC and API R&D business in India to wholly-owned subsidiaries during FY26:
- OTC business to Lupinlife Consumer Healthcare Limited for ₹8,200.0 million (gain: ₹6,589.6 million)
- API R&D business to Lupin Manufacturing Solutions Limited for ₹180.0 million (gain: ₹37.2 million)
Impairment:
Recognized impairment charge of ₹879.1 million (Q4 FY26) and ₹1,130.1 million (FY26) related to capital work-in-progress, intangible assets, and intangible assets under development
Investment Write-down:
Provided for diminution in value of investment in a subsidiary: ₹700.0 million during FY26
Entities in Consolidation:
The consolidated results include 42 subsidiaries and 1 joint venture across multiple countries including USA, Australia, Netherlands, South Africa, Philippines, Germany, Malaysia, Mexico, Brazil, UK, France, Sri Lanka, New Zealand, Japan, Thailand, and others.